180 related articles for article (PubMed ID: 37137336)
61. Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression.
Peng H; Long F; Wu Z; Chu Y; Li J; Kuai R; Zhang J; Kang Z; Zhang X; Guan M
Biomed Res Int; 2013; 2013():181384. PubMed ID: 23509688
[TBL] [Abstract][Full Text] [Related]
62. Comprehensive analysis of epigenetic pattern of long noncoding RNA loci in colorectal cancer.
Liao Q; Chen L; Liu J; Yang T; Li J; Zhang X; Zhao J
Gene; 2016 Dec; 595(1):9-17. PubMed ID: 27642123
[TBL] [Abstract][Full Text] [Related]
63. Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer.
Rönsch K; Jäger M; Schöpflin A; Danciu M; Lassmann S; Hecht A
Epigenetics; 2011 May; 6(5):610-22. PubMed ID: 21393996
[TBL] [Abstract][Full Text] [Related]
64. Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma.
Kim HS; Yoon G; Do SI; Kim SJ; Kim YW
Oncotarget; 2016 Mar; 7(12):15187-99. PubMed ID: 26942563
[TBL] [Abstract][Full Text] [Related]
65. Methylation-Based Therapies for Colorectal Cancer.
Cervena K; Siskova A; Buchler T; Vodicka P; Vymetalkova V
Cells; 2020 Jun; 9(6):. PubMed ID: 32599894
[TBL] [Abstract][Full Text] [Related]
66. DACT2 Epigenetic Stimulator Exerts Dual Efficacy for Colorectal Cancer Prevention and Treatment.
Lu L; Wang Y; Ou R; Feng Q; Ji L; Zheng H; Guo Y; Qi X; Kong AN; Liu Z
Pharmacol Res; 2018 Mar; 129():318-328. PubMed ID: 29199082
[TBL] [Abstract][Full Text] [Related]
67. Targeting aberrant chromatin structure in colorectal carcinomas.
Konishi K; Issa JP
Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
[TBL] [Abstract][Full Text] [Related]
68. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
69. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
70. Robust prediction of gene regulation in colorectal cancer tissues from DNA methylation profiles.
Klett H; Balavarca Y; Toth R; Gigic B; Habermann N; Scherer D; Schrotz-King P; Ulrich A; Schirmacher P; Herpel E; Brenner H; Ulrich CM; Michels KB; Busch H; Boerries M
Epigenetics; 2018; 13(4):386-397. PubMed ID: 29697014
[TBL] [Abstract][Full Text] [Related]
71. Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.
Neumeyer S; Popanda O; Edelmann D; Butterbach K; Toth C; Roth W; Bläker H; Jiang R; Herpel E; Jäkel C; Schmezer P; Jansen L; Alwers E; Benner A; Burwinkel B; Hoffmeister M; Brenner H; Chang-Claude J
Epigenetics; 2019 May; 14(5):477-493. PubMed ID: 30931802
[TBL] [Abstract][Full Text] [Related]
72. Frequent epigenetic silencing of the folate-metabolising gene cystathionine-beta-synthase in gastrointestinal cancer.
Zhao H; Li Q; Wang J; Su X; Ng KM; Qiu T; Shan L; Ling Y; Wang L; Cai J; Ying J
PLoS One; 2012; 7(11):e49683. PubMed ID: 23152928
[TBL] [Abstract][Full Text] [Related]
73. Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer.
Szmida E; Karpiński P; Leszczynski P; Sedziak T; Kielan W; Ostasiewicz P; Sasiadek MM
J Appl Genet; 2015 May; 56(2):185-92. PubMed ID: 25366420
[TBL] [Abstract][Full Text] [Related]
74. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
[TBL] [Abstract][Full Text] [Related]
75. JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy.
Tan J; Wang HL; Yang J; Liu QQ; Li CM; Wang YQ; Fu LN; Gao QY; Chen YX; Fang JY
Theranostics; 2020; 10(13):5763-5777. PubMed ID: 32483417
[No Abstract] [Full Text] [Related]
76. Analyzing epigenetic control of galectin expression indicates silencing of galectin-12 by promoter methylation in colorectal cancer.
Katzenmaier EM; Kloor M; Gabius HJ; Gebert J; Kopitz J
IUBMB Life; 2017 Dec; 69(12):962-970. PubMed ID: 29098769
[TBL] [Abstract][Full Text] [Related]
77. Adipose tissue inflammation and
Castellano-Castillo D; Morcillo S; Clemente-Postigo M; Crujeiras AB; Fernandez-García JC; Torres E; Tinahones FJ; Macias-Gonzalez M
Clin Epigenetics; 2018; 10():60. PubMed ID: 29719581
[TBL] [Abstract][Full Text] [Related]
78. FOXD3, frequently methylated in colorectal cancer, acts as a tumor suppressor and induces tumor cell apoptosis under ER stress via p53.
Xu M; Zhu J; Liu S; Wang C; Shi Q; Kuang Y; Fang X; Hu X
Carcinogenesis; 2020 Sep; 41(9):1253-1262. PubMed ID: 31784734
[TBL] [Abstract][Full Text] [Related]
79. Epigenetic silencing of NDRG2 promotes colorectal cancer proliferation and invasion.
Hong SN; Kim SJ; Kim ER; Chang DK; Kim YH
J Gastroenterol Hepatol; 2016 Jan; 31(1):164-71. PubMed ID: 26250123
[TBL] [Abstract][Full Text] [Related]
80. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
